PATIENT INFO: CLINICAL TRIALS
Search Clinical Trials Parent Therapeutic Areas: Oncology | Hematology
Leukemia
State
Country
Arizona
Peoria : Merck
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
Phoenix : Phoenix Children's Hospital
A Phase II Study of Dasatinib Therapy in Children and Adolescents with Ph+ Leukemia with Resistance or Intolerance to Imatinib
California
Duarte : City of Hope
A Multi-Center, Open-Label Phase I Study of Single Agent RO5045337 Administered Orally in Patients with Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia (CML)in Blast Phase, or Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphoma (CLL/SCLL)
A Phase II Multicenter Trial of Myeloablative Double Unit Umbilical Cord Blood Transplantation (UCBT) in Adults with Hematologic Malignancy
A Phase II Study of LBH589, a Novel Histone Deacetylase Inhibitor, in Relapsed and Refractory Adult Patients with Acute Leukemia (AL)
A Phase II Study of Rituximab-ABVD in Classical Hodgkin's Lymphoma
Acquisition of Leukapheresed Peripheral Blood Mononuclear Cells from Healthy Donors for use as Support Cells in Ex-Vivo T Cell Expansions
Allogeneic Stem Cell Transplantation with a Novel Conditioning Therapy Helical Tomotherapy, Melphalan, and Fludarabine in Hematological Malignancies
BMT CTN #0501: Multi-Center, Open Label, Randomized Trial Comparing Single Versus Double Umbilical Cord Blood Transplantation in Pediatric Patients with High Risk Leukemia and Myelodysplasia
COG #AALL0434: Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia
COG #AAML0531: Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents and Young Adults
COG AALL0232: High Risk B-Precursor Acute Lymphoblastic Leukemia
COG AALL02P2: Treatment of Late Isolated Extramedullary Relapse from Acute Lymphoblastic Leukemia (ALL) (Initial CR1>18 Months) - A Group-Wide Pilot Study
COG AALL0331: Standard Risk B-Precursor Acute Lymphoblastic Leukemia
COG AALL03B1: Classification of Acute Lymphoblastic Leukemia
COG AALL03N1: Understanding the Ethnic and Racial Differences in Survival in Children with Acute Lymphoblastic Leukemia
Immune Responses in Acute Leukemia and Chronic Myeloid Leukemia
Mechanisms of Response and Resistance to STI571 in CML
Molecular Pathogenesis of Acute Leukemia and Myelodysplasia
Molecular Pathogenesis of Therapy-Related Leukemia
Phase I Study of Escalating Doses of Radiation Therapy Using Helical Tomotherapy in Combination with Fludarabine (FLU) and Melphalan (MEL) as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation in Patients with Advanced and Hematological Malignancies who Are Not Eligible for Fully Myeloblative Regimen
Phase I/II Study of SKI-606 in Philadelphia Chromosome Positive Leukemias (Wyeth No. 3160A1-200-US)
PHI-57 NCI# 7689: Phase I Trial of GTI2040 in Relapsed, Refractory, or High Risk Leukemia and Myelodysplasia
SWOG 9007: Cytogenetic Studies In Leukemia Patients
SWOG S9910: Leukemia Centralized Reference Laboratories and Tissue Repositories, Ancillary
T2005-003: A Study of Bortezomib with Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
Long Beach : Miller's Children's Hospital
Los Angeles : Merck
Orange : Children's Hospital Of Orange County
Various Cities : Research Center New!
Aggressive Systemic Mastocytosis (ASM) and Mast Cell Leukemia (MCL) Study CPKC412D2201
Colorado
Aurora : Children's Hospital
Denver : Merck
Florida
Hialeah : Merck
Georgia
Savannah : Memorial Health University Medical Center
Epratuzumab and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia COG ADVL04P2
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia COG AALL0434
Savannah : Memorial Health University Medical Center New!
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia COG AAML0531
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Erwinase Master Treatment Protocol (EMTP)
Illinois
Chicago : Merck
Hines : Merck
Indiana
Beech Grove : St. Francis Hospital and Health Centers
SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717)
Maryland
Baltimore : Johns Hopkins Medical Center
Massachusetts
Boston : Boston University Medical Center
Dendritic/AML Fusion Cell Vaccine Therapy for AML Patients in First Remission: A Phase I Clinical Trial.
Missouri
Kansas City : Childrens Mercy Hospital
Saint Louis : Merck
New Jersey
Newark : Merck
New York
Bronx : Biomedical Research Alliance of New York
Leukemia - Acute Lymphocytic (ALL)
East Syracuse : Merck
Lake Success : Biomedical Research Alliance of New York
Acute Promyelocytic Leukemia (APL) - Adults
Secondary Acute Myeloid Leukemia - Adults
New York : Mount Sinai Medical Center
A Phase I-II Pilot Study of Divalproex Sodium and All-Trans-Retinoic Acid (ATRA) in Relapsed or Refractory Acute Myeloid Leukemia (except M3, FAB Classification)
Randomized Phase II Study of Thalidomide Versus Thalidomide Plus Fludarabine for Patients with Chronic Lymphocytic Leukemia Previously Treated with Fludarabine
Rochester : Merck
Ohio
Cincinnati : Cincinnati Children's Hospital Medical Center/Cincinnati Children's Research Foundation
(ADVL0812) A Phase I Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children with Relapsed/Refractory Solid Tumors and Leukemia
A Feasibility Pilot and Phase 2 Study of Chemoimmunotherapy with Epratuzumab for Children with Relapsed CD22-Positive Acute Lymphoblastic Leukemia
ADVL0816: A Phase I Study of Obatoclax (Pan Anti-Apoptotic BCL-2 Family Small Molecule Inhibitor), in Combination with Vincristine/Doxorubicin/Dexrazoxane, in Children with Relapsed/Refractory Solid Tumors or Leukemia
Oregon
Portland : Doernbecher Children's Hospital
Pennsylvania
Philadelphia : Children'sHospital Of Phila
Pittsburgh : Children'S Hospital Of Pittsburgh
Rhode Island
Providence : Merck
Texas
Houston : Md Anderson Cancer Center
Houston : Merck
Houston : S. R. Burzynski Clinic
Phase II Study Of Antineoplaston A10 And AS2-1 In Patients With Chronic Lymphocytic Leukemia
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Chronic Myelogenous Leukemia
Virginia
Charlottesville : University of Virginia New!
Children over 10 years of age with ALL Leukemia sought for research study.
Washington
Seattle : Seattle Children's Research Institute
Seattle : Merck
Australia
South Granville : Merck Sharp & Dohme (Australia) Pty Ltd.
Leukemia Research Foundation | 3520 Lake Ave., Suite 202 | Wilmette, IL 60091 | 847.424.0600 | 847.424.0606 (fax)
The mission of the Leukemia Research Foundation is to conquer leukemia, lymphoma, and myelodysplastic syndromes by funding research into their causes and cures and to enrich the life of those touched by these diseases.
If you have any problems or suggestions with our website please contact our webmaster. ©2008 Leukemia Research Foundation | site map | privacy policy